
|Videos|January 30, 2023
Updates on Selinexor Triplet Combination Therapies from ASH 2022
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5




























